{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:27:12Z","timestamp":1790274432982,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1681\/asn.2013080830","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T02:30:54Z","timestamp":1397183454000},"page":"1083-1093","source":"Crossref","is-referenced-by-count":262,"title":["The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy"],"prefix":"10.1681","volume":"25","author":[{"given":"Dick","family":"de Zeeuw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blai","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Andress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Houser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Kohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.","family":"Lambers Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Pritchett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon W.","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Viberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20230208","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1900\/RDS.2011.8.392","article-title":"The kidney in type 2 diabetes therapy.","volume":"8","author":"Heerspink","year":"2011","journal-title":"Rev Diabet Stud"},{"key":"R2-27-20230208","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL.","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"R3-27-20230208","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.","volume":"45","author":"Atkins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R4-27-20230208","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrneph.2012.42","article-title":"Proteinuria should be used as a surrogate in CKD.","volume":"8","author":"Cravedi","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R5-27-20230208","first-page":"566","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.","volume":"21","author":"Ibsen","year":"2008","journal-title":"J Nephrol"},{"key":"R6-27-20230208","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2010091001","article-title":"Changes in albuminuria predict mortality and morbidity in patients with vascular disease.","volume":"22","author":"Schmieder","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R7-27-20230208","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: New insights.","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R8-27-20230208","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy.","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R9-27-20230208","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bcp.12064","article-title":"Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.","volume":"76","author":"Ko","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R10-27-20230208","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"R11-27-20230208","doi-asserted-by":"crossref","first-page":"11003","DOI":"10.1074\/jbc.M110.190793","article-title":"Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop.","volume":"286","author":"Simonson","year":"2011","journal-title":"J Biol Chem"},{"key":"R12-27-20230208","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria.","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R13-27-20230208","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","article-title":"Liver toxicity of sitaxentan in pulmonary arterial hypertension.","volume":"37","author":"Gali\u00e8","year":"2011","journal-title":"Eur Respir J"},{"key":"R14-27-20230208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions.","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R15-27-20230208","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-3565(25)12297-0","article-title":"Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist.","volume":"276","author":"Opgenorth","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-27-20230208","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R18-27-20230208","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/00004872-199507001-00008","article-title":"Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.","volume":"13","author":"de Zeeuw","year":"1995","journal-title":"J Hypertens Suppl"},{"key":"R19-27-20230208","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201405000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:45:03Z","timestamp":1786131903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201405000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2013080830","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718346572.793494857","asserted-by":"object"}]},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}